tbuckley/cabot-search huggingface dataset:
Phase I clinical trial outcomes in 93 patients with brain metastases: The M. D. Anderson Cancer Center experience.
Authors: N. G. Iskander, A. M. Tsimberidou, K. Letourneau, S. Wen, J. J. Wheler, D. S. Hong, A. Naing, R. Kurzrock
Journal: Journal of Clinical Oncology (2011)

e16546 Background: Patients with brain metastases are often excluded from clinical trials, but it is unclear if they pose an enhanced risk. Methods: We reviewed the records of 1,181 consecutive patients with and without brain metastases treated in the Phase I Clinical Trials Program. We compared clinical outcomes in patients who presented with and without brain metastases during the same time period. Results: Of 1,181 patients, 93 had brain metastases at the time of referral (median: age, 54 yrs, number of prior therapies, n=4). The rates of stable disease ≥ 4 months/ partial/ complete response in patients with and without brain metastases were 17% and 27%, respectively (p= 0.03). Although the median survival for patients with brain metastases was shorter than for that of patients without brain metastases (7.5 vs. 10.3 months; p = 0.002), in multivariate analysis the presence of brain metastases was not an independent factor predicting survival. There was no difference in time-to-treatment failure (TTF) (1.74 vs. 1.84 months, respectively; p = 0.61) or in Grade 3-4 toxicity (including neurologic) between patients with and without brain metastases (12% vs. 10%, p = 0.77). When treatment-related neurotoxicity ≥Grade 3-4 was compared between 93 patients with brain metastases and 527 patients without brain metastases treated in the same protocols, the respective rates were 4.3% (n=4) and 2.27% (n=12) (p 0.435). Conclusions: The rates of survival and response of patients with brain metastases were lower than those for other patients in the Phase I setting, but the presence of brain metastases was not an independent prognostic factor predicting survival, indicating that other covariates that co-exist with brain metastases were more significant. TTF for patients with brain metastases was not decreased, nor was the incidence of serious side effects (including neurotoxicity) increased, suggesting that these patients should be eligible for early clinical trials.
Case 23-1969
Authors: Warren Point, Benjamin Castleman
Journal: New England Journal of Medicine (1969)

Presentation of CaseA sixty-five-year-old woman was admitted to the hospital because of anorexia, nausea, weight loss and abdominal pain.She had been well until five weeks previously, when crampy lower abdominal discomfort developed. The discomfort increased and was associated with severe constipation. Four days before admission the pain became more severe, with radiation to the back. She did not vomit but was unable to eat solid food. There had been no fatty-food intolerance, fever, chills, diarrhea or vomiting. During the week before entry she lost 8 to 10 pounds in weight. An upper gastrointestinal series a few days before . . .
Personality, interests, and emotional disturbance in psychiatric residents
Authors: P E Garfinkel, E M Waring
Journal: American Journal of Psychiatry (1981)

To determine the personality and attitudinal characteristics of emotionally disturbed psychiatric residents and their short-term adjustment the authors conducted a series of psychological tests with physicians entering two psychiatric residency programs. Seventy residents completed the test battery, which included the General Health Questionnaire (GHQ), the MMPI, the Eysenck Personality Inventory, and the Strong Vocational Interest Blank. About 9% of the sample scored as cases on the GHQ, having nonpsychotic emotional illness, and a further 5% scored as likely cases. These physicians had significantly higher neuroticism scores and MMPI depression, social isolation, schizophrenia, psychasthenia, and hypochondriasis scores. Their interests were less like those of other physicians or psychiatrists and more like those of bankers and office workers.
Cardiac Glycosides
Authors: Dale G. Friend
Journal: New England Journal of Medicine (1962)

To understand better and more deeply appreciate the development of knowledge in this field, it is desirable to begin with the simpler aspects of the action of these glycosides and then to proceed to the more complex and perhaps more fundamental ones. The effects of the cardiac glycosides may be listed as follows:Therapeutic doses have no proved useful therapeutic effect on the normal heart, but have been shown to increase the contractile force of the actively contracting cardiac muscle. They also increase the contractile force of skeletal, venous and arterial smooth muscle. Cardiac output is not increased by the . . .
AB0641 Comparing the Characteristics of Adult and Pediatric Patients with Polyarteritis Nodosa
Authors: A. Erden, E.D. Batu, Z.S. Arici, E. Bilgin, S. Apras Bilgen, O. Karadag, I. Ertenli, S. Ozen
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Polyarteritis nodosa (PAN) as a necrotizing vasculitis of medium or small arteries without glomerulonephritis or vasculitis in arterioles, venules or capillaries and not associated with antineutrophil cytoplasmic antibodies. It is more common in middle-aged adults when compared with children. <h3>Objectives</h3> The aim of this study was to examine and compare the clinical characteristics of adult and pediatric patients with PAN. <h3>Methods</h3> Six pediatric (&lt;18 years of age) and ten adult patients with a clinical diagnosis of PAN who were seen at the Departments of Rheumatology and Pediatric Rheumatology, Hacettepe University, Ankara, Turkey were included in the study group. The pediatric and adult patients were classified as PAN according to the Ankara 2008 and American College of Rheumatology (ACR) 1990 criteria, respectively. The clinical features and response to therapy were evaluated retrospectively. <h3>Results</h3> The characteristics of PAN patients were summarized in Table 1. According to the results with a statistical significance, female/male ratio was higher in children; neurologic and renal involvements were more common and the duration of induction treatment was longer in adults. 2/10 adult and 3/6 pediatric patients had accompanying familial Mediterranean fever. Ninety percent of adult patients had received cyclophosphamide plus corticosteroid for induction treatment while four pediatric patients received CYC and two received mycophenolate mofetil besides corticosteroid treatment. <h3>Conclusions</h3> Our study, although the number is limited, have shown that neurologic and renal involvement were more common in adults with PAN and the duration of induction treatment was longer when compared with pediatric patients. There is no previous study comparing the characteristics of pediatric and adult patients with PAN; however, according to the previous studies, juvenile PAN has a more benign course than adult onset PAN. Multicenter collaboration remains essential to determine the characteristic features of PAN in patients of different age groups. <h3>References</h3> Eleftheriou D, Batu ED, Ozen S, Brogan P. Vasculitis in children. Nephrol Dial Transplant 2014 Dec 30. pii: gfu393. [Epub ahead of print]. Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010;69:798-806. Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33:1088-1093. <h3>Disclosure of Interest</h3> None declared
Epidemiology of tuberculosis in the EU/EEA in 2010 – monitoring the progress towards tuberculosis elimination
Authors: A Sandgren, V Hollo, E Huitric, C Ködmön
Journal: Eurosurveillance (2012)

The 2012 combined tuberculosis (TB) surveillance and monitoring report for the European Union and European Economic Area identifies a mean annual decline in TB notification rate by 4.4% from 2006 to 2010. Culture confirmation for new pulmonary cases and drug susceptibility testing have increased to 65.6% and 70.8%, but remain under their targets of 80% and 100%, respectively. Reporting of treatment outcome and coinfection with human immunodeficiency virus also remain suboptimal. Strengthened control practices are needed to allow progress towards TB elimination.
Atypical Antipsychotic Drugs and Alzheimer's Disease
Authors: Hadi Meeran Hussain, Matthew Hotopf, Femi Oyebode
Journal: New England Journal of Medicine (2007)

To the Editor: Schneider et al. (Oct. 12 issue)1 conclude that the adverse effects of atypical anti­ psychotic drugs for the treatment of psychosis, aggression, and agitation in patients with Alzheim­ er’s disease offset the advantages. However, they acknowledge that the doses used in the study were lower than some clinicians would have used and that patients could discontinue a study drug (a main outcome) and randomly switch to another of the study drugs. The rate of discontinuation of treatment ranged from 77 to 85% among the four study groups. An accompanying editorial by Karlawish2 high­ lights the novelty of this trial’s design, with a primary outcome that attempts to reflect actual clinical events — in other words, a situation in which a switch would be made to another atypical neuroleptic agent after 2 to 4 weeks if the first drug had side effects or no apparent benefit. There will be much discussion of this study in the coming months. One possible interpretation of the findings is that nonpharmacologic inter­ ventions and non­neuroleptic drugs should be tried before atypical antipsychotic drugs. Antide­ pressants, antiepileptic drugs, and the N­methyl­ d­aspartate (NMDA) receptor antagonist meman­ tine could be tried in individual patients to reduce the use of antipsychotic drugs. Another study by the Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer’s Disease (CATIE­AD) study group may be required to demonstrate the effectiveness of these drugs for psychosis, aggres­ sion, and agitation in patients with Alzheimer’s disease.
ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma
Authors: Jae Hyuk Yoo, Dallas S. Shi, Allie H. Grossmann, Lise K. Sorensen, ZongZhong Tong, Tara M. Mleynek, Aaron Rogers, Weiquan Zhu, Jackson R. Richards, Jacob M. Winter, Jie Zhu, Christine Dunn, Ashok Bajji, Mark Shenderovich, Alan L. Mueller, Scott E. Woodman, J. William Harbour, Kirk R. Thomas, Shannon J. Odelberg, Kirill Ostanin, Dean Y. Li
Journal: Cancer Cell (2016)
원저 : 알코올 대사 효소들의 유전적 다형성이 음주 행태 및 간경변증 발생에 미치는 영향
Authors: 기주영 ( Joo Young Kee ), 김민옥 ( Min Ok Kim ), 유일영 ( Il Young You ), 채지영 ( Ji Young Chai ), 홍의실 ( Eui Sil Hong ), 안성철 ( Sung Chul An ), 김헌 ( Heon Kim ), 박선미 ( Seon Mee Park ), 윤세진 ( Sei Jin Youn ), 채희복 ( Hee Bok Chae )
Journal: Clinical and Molecular Hepatology (2003)

목적: 만성적인 다량의 음주에도 불구하고 알코올 중독자의 15%만이 알코올성 간경변증에 이르는데, 유전학적인 차이를 포함한 간질환에 대한 개인적인 감수성의 차이가 발병에 중요한 영향을 미칠 것으로 생각된다. 이에 저자들은 정상 대조군, 과음주력이 있으나 간경변증의 증거가 없는 군, 알코올성 간경변증 환자군 간의 ALDH2, ADH2, CYP2E1, catalase의 네 가지 알코올 대사 효소의 유전자형 빈도 차이가 음주 행태 및 질환 발생을 어느 정도 설명할 수 있는 것인지를 알아보고자 하였다. 대상과 방법: 정상 성인 42명을 정상 대조군(평균연령 52±9세)으로, 임상적 혹은 방사선학적으로 알코올성 간경변증이 확실하게 증명된 30명을 알코올성 간경변증군(평균연령 52±9세)으로, 음주력은 있으나 간질환의 증거가 없는 12명을 과음주자군(평균연령 46±6세)으로 배정하였다. 환자의 말초혈액 백혈구에서 DNA를 추출한 후, ALDH2, CYP2E1, ADH2, catalase1 유전자에 대해 PCR을 시행한 후 제한 효소들로 처리하여 제한분절길이 다형성으로 유전자형을 나누어 각 유전자형의 출현 빈도를 비교하였다. 결과: 1) 본 연구에서 검사한 정상 성인 남자 42예에서 알코올 대사 효소들의 유전자형 빈도는 ADH2는 (1＊1), (1＊2)가 38%, 36%, ADLH2 (1＊1)(야생형), (1＊2), (2＊2)이 각각 69%, 28%, 2%의 비율로 나타났다. CYP2E1의 경우 c1/c1(야생형) 유전자형이 55%를 차지하였다. catalase1의 경우 TT(야생형)유전자형이 12%를 차지하였다. 2) 정상 대조군과 음주자군(과음주자군과 알코올성 간경변증 환자군의 합)간에 ALDH2 (1＊2) 혹은 (2＊2) 유전자형 빈도가 유의하게 음주자군에서 낮음을 알 수 있었다. 음주자군 중에서는 ALDH2 효소의 결핍형 동형접합체 ALDH (2＊2)는 한 예도 없었으며 이형접합체만이 5예였으며, 나머지는 모두 야생형 동형접합체(88%)였다. 3) 정상대조군과 음주자 간에 ADH2, CYP2E1, catalase1 유전자의 유전자형 분포의 차이를 관찰할 수 없었다. 결론: ALDH2 결핍 유전자형 존재는 개인의 음주 행태에 영향을 미치는 인자이나, 음주자군에서 그 결핍 빈도가 낮아 알코올성 간경변증 발병에 미치는 영향을 임상 연구를 통하여 규명하기에는 제한점이 있었다. ADH2, CYP2E1, CAT1 유전자의 경우에는 세 군 간에 서로 의미 있는 차이가 없어 질병 발생과, 음주 행태에 있어서 이 유전자들의 역할은 미미할 것으로 생각된다.
Differences in toxicity findings for antiestrogens.
Authors: G M Williams
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.5.1999 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9586922 Differences in toxicity findings for antiestrogens. G M WilliamsxG M WilliamsSearch for articles by this author https://doi.org/10.1200/JCO.1998.16.5.1999 PDF "Differences in toxicity findings for antiestrogens.." Journal of Clinical Oncology, 16(5), pp. 1999–2000© 1998 by American Society of Clinical Oncology
Landscape of tumor-infiltrating T cell repertoire of human cancers
Authors: Bo Li, Taiwen Li, Jean-Christophe Pignon, Binbin Wang, Jinzeng Wang, Sachet A Shukla, Ruoxu Dou, Qianming Chen, F Stephen Hodi, Toni K Choueiri, Catherine Wu, Nir Hacohen, Sabina Signoretti, Jun S Liu, X Shirley Liu
Journal: Nature Genetics (2016)
Effect of Cortisone Administration on Induced and Transplanted Hepatomas&lt;xref ref-type="fn" rid="fn1"&gt;1&lt;/xref&gt;, &lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: Cornelia Hoch-Ligeti
Journal: JNCI Journal of the National Cancer Institute (1955)

Effect of Cortisone Administration on Induced and Transplanted Hepatomas, Get access Cornelia Hoch-Ligeti Cornelia Hoch-Ligeti Department of Pathology, School of Medicine, University of Virginia, Charlottesville, Va. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue Supplement_5, April 1955, Pages 1633–1636, https://doi.org/10.1093/jnci/15.Supplement_5.1633 Published: 01 April 1955
Effects of Complement<i>C4</i>Gene Copy Number Variations, Size Dichotomy, and<i>C4A</i>Deficiency on Genetic Risk and Clinical Presentation of Systemic Lupus Erythematosus in East Asian Populations
Authors: Ji Yih Chen, Yee Ling Wu, Mo Yin Mok, Yeong‐Jian Jan Wu, Katherine E. Lintner, Chin‐Man Wang, Erwin K. Chung, Yan Yang, Bi Zhou, Huanyu Wang, Denise J. H. C. Yu, Alaaedin Alhomosh, Karla Jones, Charles H. Spencer, Haikady N. Nagaraja, Yu Lung Lau, Chak‐Sing Lau, C. Yung Yu
Journal: Arthritis & Rheumatology (2016)

Human complement C4 is complex, with multiple layers of diversity. The aims of this study were to elucidate the copy number variations (CNVs) of C4A and C4B in relation to disease risk in systemic lupus erythematosus (SLE), and to compare the basis of race-specific C4A deficiency between East Asians and individuals of European descent.
Clonal Stimulation or Inhibition of Human Colon Carcinomas and Human Renal Carcinomas Mediated by Transforming Growth Factor-β 1
Authors: Dominic Fan, Subhas Chakrabarty, Christopher Seid, Carl W. Bell, Hans Schackert, Kiyoshi Morikawa, Isaiah J. Fidler
Journal: Cancer Communications (1989)

We examined various human carcinomas and cells populating a single human neoplasm to determine whether they exhibit a heterogeneous response to the effects of transforming growth factor-beta 1 (TGF-beta). Using recently established human colon carcinoma and renal cell carcinoma under defined in vitro conditions, we observed intertumoral and intratumoral heterogeneity and polarity of responses to TGF-beta (growth inhibition or stimulation) that did not correlate with the metastatic phenotype of the cancer cells as assessed in athymic nude mice. TGF-beta mediated both cytostatic and cytolytic effects against sensitive tumor cells, and these responses were not related to the effects of TGF-beta on the cell-cycle traverse. The human colon carcinoma and renal cell carcinoma, however, exhibited differences in the expression of TGF-beta receptors.
Abstract 5796: Real-Time 3D Transesophageal Echo Enhances the Diagnostic Capabilities of Patent Foramen Ovale in Patient’s with Cerebral Vascular Accidents
Authors: Edward A Gill, Michael A Chen, Pathmaja Paramsothy, Peter J Cawley, Francis Kim, Joshua M Buckler
Journal: Circulation (2008)

Real-time 3D transesophageal echo (RT3D TEE) is a novel technology whereby RT3D rendering of ultrasound images is performed resulting in unique views of cardiac structures. We have presented initial data reporting the incidence of optimal en face visualization of cardiac structures including the fossa ovalis (FO). We aimed to further characterize the FO. Therefore, our hypotheses were that the FO could be seen en face in full circumferential view (CV) in most patients and saline contrast RT3D TEE would enhance the accuracy of patent foramen ovale (PFO) diagnosis compared to contrast 2D TEE. Therefore, in an unselected series of 124 patients referred for TEE, we performed RT3D TEE with specific views of the FO using the Philips x7–2t RT3D TEE transducer. Images of the FO were acquired in the real-time 3D, 3D zoom, and full volume modes. Visualization of the FO was scored by 2 separate observers using the following scale: full CV of the FO &gt;1/2 CV &lt;1/2 CV no visualization. The visualization score was 1.44. The average maximal and minimal diameters of the FO during the cardiac cycle were 1.46±0.90 and 1.12±0.12cm and an average maximum area of 169±20mm2. The sensitivity of saline contrast RT3DTEE for PFO diagnosis was 100% with specificity of 96% due to 3 cases where PFO was seen only by RT3D TEE. RT3DTEE allows complete circumferential visualization of the FO in the majority of cases. Our determination of the size of the FO compares favorably with pathologic series Some cases of PFO can be expected to be detected only by RT3DTEE and therefore this technique should be performed when 2D TEE is negative for PFO but clinical suspicion remains high.
OP0114 A Proliferative Inducing Ligand (April) Promotes IL-10 Production by Human B Cells
Authors: C. Hua, R. Audo, M. Hahne, B. Combe, J. Morel, C. Daïen
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> B cells may have a negative regulatory role, mainly mediated by interleukin 10 (IL-10). We recently showed that regulatory B cell functions are impaired in patients with rheumatoid arthritis (RA) and that a proliferation inducing ligand (APRIL) transgenic mice are protected against collagen induced arthritis. <h3>Objectives</h3> We aimed to explore the effect of APRIL on normal human B cell IL-10 production. <h3>Methods</h3> CpG induced IL-10 B cell production was compared in presence or absence of APRIL and B lymphocyte stimulating factor (BLys). The expression of the BLyS and APRIL receptor transmembrane activator and CAML interactor (TACI) and of BLyS specific receptor (BAFF-R) was compared between IL-10 producing and non-producing B cells. The effect of APRIL stimulated B cells on T cell cytokine production was analyzed after 3 days of co-culture. Signaling pathways of B cells activated by CpG and APRIL were analyzed by western blot. Similar experiments were performed on cells of RA patients. <h3>Results</h3> APRIL but not BLyS promotes IL-10 production by B cells (9.5 [6.8-13.2] vs 6.2 [3.9-7.0] vs 4.2 [3.3-8.0] % for APRIL, BLyS and culture medium alone respectively, APRIL vs media p=0.002 and APRIL vs BLyS p=0.007).The effect was abrogated by co-culturing of TACI-Fc. IL-10 producing B cells expressed significantly more TACI (7.1 [5.5-16.8] vs 2.4 [1.9-7.8]%; p=0.016) and less BAFF-R (2.3 [2.0-2.5] vs 2.7 [2.3-2.8] of mean fluorescence intensity; p=0.021) than non- IL-10 producing B cells. APRIL stimulated B cells decreased TNF-α (-36±13%, p=0.02) and IFN-γ (-14±3%; p=0.02) secretion of T cells compared to non-stimulated B cells but not IL-17 production (-14±14%, p=0.31). APRIL further stimulated CpG activated STAT3, ERK and JNK pathways. APRIL also promoted IL-10 production of B cells in RA patients and similar pattern of APRIL and BLyS receptors on IL-10 producing B cells were observed in RA patients and in controls. <h3>Conclusions</h3> We show for the first time that APRIL but not BLyS promotes IL-10 production by B cells and enhances the regulatory role of B cells on T cells by decreasing TNF-a and IFN-g by T cells. IL-10 producing B cells of RA patients are responsive to APRIL suggesting a possible therapeutic application by expanding B10 cells of these patients. <h3>Disclosure of Interest</h3> None declared
Haploidentical TCRab Depleted Hematopoietic Cell Transplantation Leads To Rapid Immune Reconstitution and Promising Clinical Outcome In Adults
Authors: Sebastian P. Haen, Michael Schumm, Wichard Vogel, Christoph Faul, Rupert Handgretinger, Lothar Kanz, Wolfgang A. Bethge
Journal: Blood (2013)
SP0154 ”Social Participation is Important to Me”; The Experience of Adults with Rheumatoid Arthritis
Authors: M. Björk
Journal: Annals of the Rheumatic Diseases (2015)

"To be able to do what I want to do" is a common goal for the rehabilitation of patients with Rheumatoid Arthritis (RA). New biological medications and earlier multiprofessional intervention has led to a reduction in the extent of disability for patients. However disability remains a key problem for patients and challenge for health professionals. For example, in the Swedish TIRA-project (Early Interventions in Rheumatoid Arthritis), patients of working age report a high number of participation restrictions in work, leisure and social activities despite early interventions, including biological medication and multi-professional treatment. As a consequence these patients experience emotions such as anger and frustration because they are unable to fulfil their roles and valued activities. This session will present an overview of how men and women of working age with RA describe what participation is to them and the potential for them to participate in their daily activities in the way they want to. It will further discuss if today9s patients with RA experience an increased need to be able to participate in society and the implications of this for rehabilitation. <h3>Disclosure of Interest</h3> None declared
Alternative Healer
Authors: Dean Gianakos
Journal: Annals of Internal Medicine (2000)

On Being a Doctor3 October 2000Alternative HealerDean Gianakos, MDDean Gianakos, MDLynchburg Family Practice Residency; Lynchburg, VA 24501 (Gianakos)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-7-200010030-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The sign on the front door reads: Practitioner of the Alternative, Healing Arts. I quickly took a seat in the waiting room. Rugs, curtains, and a fireplace in the corner warmed me. I recognized a few smiling faces (former patients?) as I picked up a magazine resting on an old mahogany table. After the receptionist called me to the window a few minutes later, a friendly nurse escorted me to an examination room.The doctor introduced himself as a practitioner of alternative medicine. He was dressed comfortably and appeared in no hurry. After some polite banter about the weather and ... Author, Article, and Disclosure InformationAffiliations: Lynchburg Family Practice Residency; Lynchburg, VA 24501 (Gianakos)Corresponding Author: Dean Gianakos, MD, Lynchburg Family Practice Residency, 2097 Langhorne Road, Lynchburg, VA 24501; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPatterns of Complementary and Alternative Medicine Use among Turkish Cancer PatientsRegaining Our Humanity Through StorySharing the spirit of the policy agenda? Private complementary therapists’ attitudes towards practising in the British NHSIntegrative MedicineDeterminants of the Use of Complementary Therapies by Patients With Cancer 3 October 2000Volume 133, Issue 7Page: 559KeywordsBloodBlood pressureNursesResidencyShouldersSystematic reviews ePublished: 3 October 2000 Issue Published: 3 October 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...